Aptose Presents New CG-806 Data at the 23rd Congress of the European Hematology Association
Aptose Biosciences, Inc. - Common Shares (APTO)
Last aptose biosciences, inc. - common shares earnings: 3/10 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aptose.com/investors
Company Research
Source: GlobeNewswire
STOCKHOLM, Sweden and SAN DIEGO, June 15, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the presentation of preclinical data demonstrating that CG-806, a highly potent pan-FLT3/pan-BTK inhibitor, exhibits a distinct mechanism of action and greater potency on patient-derived hematologic cancer cells than ibrutinib, a BTK inhibitor approved for the treatment of certain hematologic malignancies. The data were presented in a poster on Friday, June 15, at the 23rd Congress of the European Hematology Association (EHA), taking place June 14-17, 2018 in Stockholm, Sweden. CG-806 is an oral small molecule pan-FLT3/pan-BTK inhibitor being developed by Aptose for acute myeloid leukemia (AML) and B-cell malignancies. It is a highly potent, reversible (non-covalent) inhibitor of the wild type and mutant forms of the Bruton’s tyrosine kinase (BTK) enzymes. Ibrutinib, a covalent BTK inhibitor approved for chronic lymphocytic leukemia (CLL) and certain B-
Show less
Read more
Impact Snapshot
Event Time:
APTO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APTO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APTO alerts
High impacting Aptose Biosciences, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
APTO
News
- Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 [Yahoo! Finance]Yahoo! Finance
- Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024GlobeNewswire
- Aptose Biosciences Inc. (NASDAQ: APTO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $5.00 price target on the stock.MarketBeat
- Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
APTO
Earnings
- 11/9/23 - Beat
APTO
Analyst Actions
- 3/27/24 - HC Wainwright
APTO
Sec Filings
- 5/10/24 - Form 4
- 5/6/24 - Form 8-K
- 5/1/24 - Form 8-K
- APTO's page on the SEC website